The Effects of Single Pill Combinations on Adherence and Blood Pressure Control in Hypertensive Patients.
Adherence
Ambulatory blood pressure monitoring
Arterial hypertension
Single pill combination
Journal
Materia socio-medica
ISSN: 1512-7680
Titre abrégé: Mater Sociomed
Pays: Bosnia and Herzegovina
ID NLM: 101281595
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
05
05
2022
accepted:
16
06
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
ppublish
Résumé
Hypertension is the most important risk factor for cardiovascular morbidity and mortality. Blood pressure control rates are as low as 17% to 31% in patients diagnosed with hypertension in high-income countries; control rates are likely poorer in low- to middle- and low-income countries. Blood pressure control rates are as low as 17% to 31% in patients diagnosed with hypertension in high-income countries; control rates are likely poorer in low- to middle- and low- income countries. Overall, 43% to 66% of patients fail to adhere to their prescribed antihypertensive medications, and after 1 year, ≈40% of patients with hypertension may stop their initial drug treatment. The aim of the study was to evaluate the effects of single pill combination antihypertensive drugs on the adherence to treatment, blood pressure control and cardiovascular events vs. free-combination therapy. We enrolled 192 adult hypertensive patients not older than 79 years, with untreated or uncontrolled hypertension despite previously receiving free combination antihypertensive therapy, between November 2020 and March 2022. Patients treated with single pill combination (SPC) were compared with an arm of the same size (n = 96) and matched by age and gender who received a standard free combination (FC) antihypertensive therapy. There were significant reductions from baseline to month 6 of follow-up in office SBP in the SPC group vs. reduction in FC group (21.9 vs. 13.1 mmHg; p < 0.0001). There were significant reductions from baseline to month 6 of follow-up in office DBP in the SPC group vs. group with free-combination therapy (13.7 vs. 8.0 mmHg; p < 0.0001). At 6 months, 94 participants (98%) were still prescribed the SPC therapy. At the final 6-month study visit, 84.2% of patients in the SPC therapy group were adherent to the prescribed antihypertensive therapy vs. 52% of patients in the FC group. Target BP values (mean 24h ambulatory systolic/diastolic BP < 130/80 mmHg) were reached by more recipients of SPC than free-combination therapy (78.2% vs. 46.3%, p < 0.05) at month 6 of follow-up. Treatment with single pill combinations (SPC), is the emerging best practice for safe, effective, rapid, and convenient hypertension control. It improves the affordability, adherence and control of arterial hypertension.
Sections du résumé
Background
UNASSIGNED
Hypertension is the most important risk factor for cardiovascular morbidity and mortality. Blood pressure control rates are as low as 17% to 31% in patients diagnosed with hypertension in high-income countries; control rates are likely poorer in low- to middle- and low-income countries. Blood pressure control rates are as low as 17% to 31% in patients diagnosed with hypertension in high-income countries; control rates are likely poorer in low- to middle- and low- income countries. Overall, 43% to 66% of patients fail to adhere to their prescribed antihypertensive medications, and after 1 year, ≈40% of patients with hypertension may stop their initial drug treatment.
Objective
UNASSIGNED
The aim of the study was to evaluate the effects of single pill combination antihypertensive drugs on the adherence to treatment, blood pressure control and cardiovascular events vs. free-combination therapy.
Methods
UNASSIGNED
We enrolled 192 adult hypertensive patients not older than 79 years, with untreated or uncontrolled hypertension despite previously receiving free combination antihypertensive therapy, between November 2020 and March 2022. Patients treated with single pill combination (SPC) were compared with an arm of the same size (n = 96) and matched by age and gender who received a standard free combination (FC) antihypertensive therapy.
Results
UNASSIGNED
There were significant reductions from baseline to month 6 of follow-up in office SBP in the SPC group vs. reduction in FC group (21.9 vs. 13.1 mmHg; p < 0.0001). There were significant reductions from baseline to month 6 of follow-up in office DBP in the SPC group vs. group with free-combination therapy (13.7 vs. 8.0 mmHg; p < 0.0001). At 6 months, 94 participants (98%) were still prescribed the SPC therapy. At the final 6-month study visit, 84.2% of patients in the SPC therapy group were adherent to the prescribed antihypertensive therapy vs. 52% of patients in the FC group. Target BP values (mean 24h ambulatory systolic/diastolic BP < 130/80 mmHg) were reached by more recipients of SPC than free-combination therapy (78.2% vs. 46.3%, p < 0.05) at month 6 of follow-up.
Conclusion
UNASSIGNED
Treatment with single pill combinations (SPC), is the emerging best practice for safe, effective, rapid, and convenient hypertension control. It improves the affordability, adherence and control of arterial hypertension.
Identifiants
pubmed: 36276180
doi: 10.5455/msm.2022.34.130-135
pmc: PMC9481967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
130-135Informations de copyright
© 2022 Nabil Naser, Zaim Jatic, Sevleta Avdic.
Déclaration de conflit d'intérêts
None declared.
Références
J Hypertens. 2019 Sep;37(9):1768-1774
pubmed: 30986788
Mater Sociomed. 2020 Mar;32(1):71-76
pubmed: 32410896
Am J Med. 2009 Mar;122(3):290-300
pubmed: 19272490
Mater Sociomed. 2020 Jun;32(2):158-164
pubmed: 32843866
Glob Heart. 2022 Jan 25;17(1):6
pubmed: 35174047
Mater Sociomed. 2011;23(3):171-83
pubmed: 23922510
BMC Fam Pract. 2011 Jun 26;12:59
pubmed: 21703010
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
Mater Sociomed. 2017 Dec;29(4):231-236
pubmed: 29284990
J Hypertens. 2008 Apr;26(4):819-24
pubmed: 18327094
Am J Med. 2007 Aug;120(8):713-9
pubmed: 17679131
Hypertension. 2013 Aug;62(2):218-25
pubmed: 23753412
J Hypertens. 2013 Apr;31(4):766-74
pubmed: 23337469
Medicine (Baltimore). 2017 Jan;96(4):e5641
pubmed: 28121920
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Med Arch. 2017 Oct;71(5):316-319
pubmed: 29284897
J Am Soc Hypertens. 2018 Aug;12(8):579.e1-579.e73
pubmed: 30219548
Int J Prev Med. 2018 Jan 15;9:4
pubmed: 29441181
J Hypertens. 2020 Dec;38(12):2369-2377
pubmed: 32833920
Cochrane Database Syst Rev. 2017 Jan 13;1:CD010316
pubmed: 28084624
Med Arh. 2010;64(5):260-3
pubmed: 21287948
J Hypertens. 2020 Jun;38(6):1016-1028
pubmed: 32371789
Hypertension. 2020 Jun;75(6):1334-1357
pubmed: 32370572
J Med Virol. 2022 Jun;94(6):2402-2413
pubmed: 35099819
J Am Heart Assoc. 2017 Nov 18;6(11):
pubmed: 29151036
Acta Inform Med. 2022 Mar;30(1):69-75
pubmed: 35800905
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Rev Esp Cardiol. 2008 Jun;61(6):644-50
pubmed: 18570788
Med Arch. 2016 Jul 27;70(4):274-279
pubmed: 27703288
Hypertension. 2013 Feb;61(2):309-18
pubmed: 23184383
Hypertension. 2018 Jun;71(6):997-1009
pubmed: 29712746
Heart. 2008 Jun;94(6):e19
pubmed: 18480341
Arch Med Sci. 2018 Aug;14(5):1125-1136
pubmed: 30154897